US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pacer WealthShield ETF

31.53

-0.1890-0.60%

Post-market: 31.620.0947+0.30%16:10 EDT

Volume:1.91K

Turnover:60.22K

Market Cap:29.95M

PE:- -

High:31.62

Open:31.52

Low:31.52

Close:31.71

52wk High:33.71

52wk Low:28.76

Shares:950.00K

Float Shares:800.00K

Volume Ratio:0.05

T/O Rate:0.24%

Dividend:0.47

Dividend Rate:1.50%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

AFT Pharmaceuticals Wins Court of Appeal Case Over Pascomer Profits

MT Newswires Live

Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

Press Release: Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PWS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PWS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","market":"US","secType":"STK","nameCN":"Pacer WealthShield ETF","latestPrice":31.5253,"timestamp":1774641600000,"preClose":31.7143,"halted":0,"volume":1906,"hourTrading":{"tag":"盘后","latestPrice":31.62,"preClose":31.5253,"latestTime":"16:10 EDT","volume":6,"amount":189.1518,"timestamp":1774642204609,"change":0.0947,"changeRate":0.003004,"amplitude":0},"delay":0,"changeRate":-0.005959456775019472,"floatShares":800000,"shares":950000,"eps":0,"marketStatus":"Market Closed","change":-0.189,"latestTime":"03-27 16:00:00 EDT","open":31.52,"high":31.62,"low":31.52,"amount":60223.3314,"amplitude":0.003153,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"CBOE","adjPreClose":31.7143,"sharesOutstanding":950000,"nav":31.72,"aum":30134000,"dividendRate":0.014988,"bidAskSpread":0.000589,"postHourTrading":{"tag":"盘后","latestPrice":31.62,"preClose":31.5253,"latestTime":"16:10 EDT","volume":6,"amount":189.1518,"timestamp":1774642204609,"change":0.0947,"changeRate":0.003004,"amplitude":0},"volumeRatio":0.053914303137657354},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","floatShares":800000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.053914303137657354,"shares":950000,"dividePrice":0.4725,"high":31.62,"amplitude":0.003153,"preClose":31.7143,"low":31.52,"week52Low":28.76,"pbRate":"--","week52High":33.71,"institutionHeld":0,"latestPrice":31.5253,"eps":0,"divideRate":0.014988,"volume":1906,"delay":0,"ttmEps":0,"open":31.52,"prevYearClose":32.3237,"prevWeekClose":31.54,"prevMonthClose":33.2698,"prevQuarterClose":32.3237,"fiveDayClose":31.54,"twentyDayClose":33.2698,"sixtyDayClose":32.548},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PWS\",params:#limit:5,,,undefined,":[{"date":"2026-03-05","symbol":"PWS","amount":0.016362,"announcedDate":"2026-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-05","defaultRemindTime":1772721000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-09","payableDate":"2026-03-05","currency":"USD","dateTimestamp":1772686800000,"payDate":"2026-03-09"},{"date":"2025-12-30","symbol":"PWS","amount":0.25921895,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-05","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-05"},{"date":"2025-09-04","symbol":"PWS","amount":0.0796608,"announcedDate":"2025-09-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-04","defaultRemindTime":1756992600000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-10","payableDate":"2025-09-04","currency":"USD","dateTimestamp":1756958400000,"payDate":"2025-09-10"},{"date":"2025-06-05","symbol":"PWS","amount":0.116206,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-05","defaultRemindTime":1749130200000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-11","payableDate":"2025-06-05","currency":"USD","dateTimestamp":1749096000000,"payDate":"2025-06-11"},{"date":"2025-03-06","symbol":"PWS","amount":0.059681,"announcedDate":"2025-03-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-06","defaultRemindTime":1741271400000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-12","payableDate":"2025-03-06","currency":"USD","dateTimestamp":1741237200000,"payDate":"2025-03-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PWS\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-27","recordDate":"2018-03-28","paymentDate":"2018-03-29","value":0.0522982,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-06-28","value":0.0481106,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-09-27","value":0.1105742,"currency":"USD"},{"executeDate":"2018-12-24","recordDate":"2018-12-26","paymentDate":"2018-12-27","value":0.0682115,"currency":"USD"},{"executeDate":"2019-03-26","recordDate":"2019-03-27","paymentDate":"2019-03-28","value":0.1385698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PWS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PWS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621084925","title":"Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084925","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084925?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296300,"startTime":"0","endTime":"0","summary":"Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 AR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260833/0/en/Aardvark-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","LU0128526141.USD","LU1803068623.USD","AARD","LU0029864427.USD","HERO","LU0029874061.USD","LU0211327993.USD","LU1267930573.SGD","LU0054578231.USD","LU0211328371.USD","LU0708994859.HKD","LU1267930490.SGD","CCK","LU0310799852.SGD","LU0310800379.SGD","BK4126","PWS","LU1892829315.USD","BK4007"],"gpt_icon":0},{"id":"2618692420","title":"AFT Pharmaceuticals Wins Court of Appeal Case Over Pascomer Profits","url":"https://stock-news.laohu8.com/highlight/detail?id=2618692420","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618692420?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:16","pubTimestamp":1773015366,"startTime":"0","endTime":"0","summary":"AFT Pharmaceuticals  said that the court of appeal has dismissed PBL Solutions' bid to claim a share of profits from the company's use of its topical skin medicine Pascomer for treating port wine stains , according to a Monday filing with the Australian and New Zealand bourses.The ruling allows the company to retain full profits from Pascomer's use in treating non-orphan conditions like PWS, per the filing.PBL, holding a 35% stake in AFT Orphan Pharmaceuticals, will receive 35% of any profits from Pascomer orphan drug applications, the filing said.PBL and the company will share the appeal costs, and the company does not expect the judgment to materially affect its fiscal year 2026 earnings guidance, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PWS","AFP.AU","AFT","BK7096"],"gpt_icon":0},{"id":"2614050774","title":"Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR","url":"https://stock-news.laohu8.com/highlight/detail?id=2614050774","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614050774?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:01","pubTimestamp":1772053260,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Feb.  25, 2026  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244960/0/en/Soleno-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Update-on-U-S-Launch-of-VYKAT-XR.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","PWS","BK4139"],"gpt_icon":0},{"id":"2613719807","title":"Press Release: Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719807","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719807?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:30","pubTimestamp":1771936200,"startTime":"0","endTime":"0","summary":"WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 -- $1.04 Billion on Track for Blockbuster Status in Narcolepsy. Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise. Pitolisant GR NDA Submission on Track for Q2 2026; Extends the Pitolisant Franchise into the 2040s. Exploring New Opportunities to Broaden the Pitolisant Franchise Beyond Orphan/Rare into Larger CNS Indications. Potential Best-In-Class Orexin-2 Agonist  Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026. Fourth Quarter and Full Year 2025 Net Product Revenue for WAKIX. --  Net product revenue for the quarter ended December 31, 2025, was $243.8. million, compared to $201.3 million for the same period in 2024. 8,500 patients in Q4 2025; representing the third consecutive quarter of. --  Net revenue projected between $1.0 billion to $1.04 billion for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","BK4022","R","BK4007","BK4232","PWS"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PWS\",params:#limit:6,delay:false,,,undefined,":[]}}